. 2015 Oct 16;6(36):39018–39027. doi: 10.18632/oncotarget.5730

Table 4. Multivariate analyses of prognostic factors of OS and PFS (landmark group, n = 122).

Baseline and clinical features		OS (without TVC)			OS (with TVC)			PFS (without TVC)			PFS (with TVC)
Baseline and clinical features		HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
CIN	Absent	1.00			1.00			1.00			1.00
	Moderate	0.59	0.31–1.13	0.109	0.44	0.21–0.95	0.035	0.35	0.20–0.64	0.001	0.24	0.12–0.48	< 0.001
	Severe	1.01	0.51–1.98	0.982	0.66	0.32–1.38	0.267	0.43	0.23–0.81	0.009	0.31	0.16–0.62	0.001
Differentiation grade	Low/undifferentiated	1.00			1.00			1.00			1.00
	Moderate/high	0.70	0.33–1.48	0.352	0.75	0.36–1.58	0.445	0.66	0.29–1.49	0.314	0.63	0.28–1.42	0.264
	Unclassified	0.92	0.52–1.63	0.778	0.92	0.52–1.62	0.771	0.86	0.52–1.45	0.577	0.83	0.50–1.38	0.465
Heterochronous (relapse from radical surgery)								0.42	0.22–0.78	0.006	0.44	0.24–0.83	0.011
Liver metastasis		2.05	1.23–3.41	0.006	2.01	1.20–3.38	0.008
Lung metastasis		2.33	1.05–5.17	0.038	2.30	1.03–5.12	0.041
Ascites and/or pleural effusion		3.49	1.95–6.24	< 0.001	3.58	1.97–6.52	< 0.001	2.04	1.27–3.27	0.003	1.92	1.20–3.09	0.007
Baseline hemoglobin > median (120.5 g/L)		0.71	0.43–1.16	0.175	0.76	0.47–1.24	0.268	0.71	0.46–1.10	0.129	0.75	0.49–1.15	0.183
Baseline platelet count > median (241 × 10⁹/L)								0.94	0.57–1.53	0.792	1.00	0.62–1.62	0.996